PORTON PHARMA SOLUTIONS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.32 CNY | +0.14% |
|
-5.67% | -43.06% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,767 | 19,821 | 48,697 | 22,305 | 13,735 | 7,819 | - | - |
| Enterprise Value (EV) 1 | 7,767 | 19,821 | 48,697 | 22,305 | 13,735 | 7,819 | 7,819 | 7,819 |
| P/E ratio | 40.9 x | 60.9 x | 92.2 x | 11.1 x | 51.3 x | 19.6 x | 14.1 x | 28.1 x |
| Yield | 0.73% | 0.33% | 0.22% | 2.71% | 1.94% | 1.71% | 2.13% | - |
| Capitalization / Revenue | 5.01 x | 9.57 x | 15.7 x | 3.17 x | 3.75 x | 2.56 x | 1.72 x | 1.78 x |
| EV / Revenue | 5.01 x | 9.57 x | 15.7 x | 3.17 x | 3.75 x | 2.56 x | 1.72 x | 1.78 x |
| EV / EBITDA | 24.9 x | 41 x | 66.4 x | 8.9 x | 23.4 x | 12.3 x | 7.38 x | 8.25 x |
| EV / FCF | - | - | - | 16,016,985 x | - | - | - | - |
| FCF Yield | - | - | - | 0% | - | - | - | - |
| Price to Book | 2.53 x | 5.84 x | 12.2 x | 3.72 x | 2.37 x | 1.38 x | 1.21 x | 1.32 x |
| Nbr of stocks (in thousands) | 542,748 | 542,748 | 544,405 | 546,027 | 546,120 | 546,038 | - | - |
| Reference price 2 | 14.31 | 36.52 | 89.45 | 40.85 | 25.15 | 14.32 | 14.32 | 14.32 |
| Announcement Date | 2/25/20 | 2/24/21 | 2/28/22 | 3/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,551 | 2,072 | 3,105 | 7,035 | 3,667 | 3,052 | 4,533 | 4,404 |
| EBITDA 1 | 311.8 | 483.9 | 733.8 | 2,507 | 588 | 634.5 | 1,060 | 948 |
| EBIT 1 | 194.7 | 352.2 | 565.6 | 2,265 | 268.9 | -43 | 517.8 | 263 |
| Operating Margin | 12.55% | 17% | 18.21% | 32.2% | 7.33% | -1.41% | 11.42% | 5.97% |
| Earnings before Tax (EBT) 1 | 193.4 | 363.7 | 548.8 | 2,246 | 246.6 | -53 | 509 | 243 |
| Net income 1 | 185.6 | 324.4 | 523.9 | 2,005 | 266.9 | 398.7 | 555 | 277 |
| Net margin | 11.96% | 15.66% | 16.87% | 28.51% | 7.28% | 13.07% | 12.24% | 6.29% |
| EPS 2 | 0.3500 | 0.6000 | 0.9700 | 3.690 | 0.4900 | 0.7314 | 1.016 | 0.5100 |
| Free Cash Flow | - | - | - | 1,393 | - | - | - | - |
| FCF margin | - | - | - | 19.8% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | 55.56% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | 69.44% | - | - | - | - |
| Dividend per Share 2 | 0.1040 | 0.1210 | 0.1930 | 1.106 | 0.4870 | 0.2450 | 0.3050 | - |
| Announcement Date | 2/25/20 | 2/24/21 | 2/28/22 | 3/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,304 | 1,817 | 3,121 | 1,378 | 960.9 | 698.3 | 630.4 | 677.7 | 1,118 | 590 | 822 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | 515.7 | 877.2 | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | 28.38% | 28.11% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | 510.6 | 867.3 | - | - | - | - | - | - | - | - |
| Net income | 830.4 | - | 427.7 | 793.1 | - | - | - | - | - | - | - | - |
| Net margin | - | - | 23.53% | 25.41% | - | - | - | - | - | - | - | - |
| EPS | 1.510 | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/19/22 | 10/25/22 | 3/24/23 | 3/24/23 | 4/21/23 | 8/18/23 | 10/27/23 | 4/26/24 | 4/26/24 | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | 1,393 | - | - | - | - |
| ROE (net income / shareholders' equity) | 6.25% | 10.1% | 14.2% | 40.3% | 4.6% | 5.83% | 7.5% | 4.7% |
| ROA (Net income/ Total Assets) | - | - | 7.98% | 24% | - | 1.7% | 5.18% | - |
| Assets 1 | - | - | 6,562 | 8,353 | - | 23,455 | 10,719 | - |
| Book Value Per Share 2 | 5.650 | 6.250 | 7.310 | 11.00 | 10.60 | 10.40 | 11.80 | 10.90 |
| Cash Flow per Share 2 | 0.6500 | 0.9300 | 0.8900 | 4.700 | 1.150 | 1.270 | 1.480 | 1.620 |
| Capex 1 | 170 | 393 | 770 | 1,172 | 1,128 | 710 | 708 | - |
| Capex / Sales | 10.98% | 18.97% | 24.8% | 16.66% | 30.74% | 23.26% | 15.62% | - |
| Announcement Date | 2/25/20 | 2/24/21 | 2/28/22 | 3/24/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
14.32
CNY
Average target price
26.65
CNY
Spread / Average Target
+86.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.06% | 1.08B | |
| +42.83% | 750B | |
| +34.11% | 606B | |
| -5.70% | 356B | |
| +18.06% | 326B | |
| +4.63% | 286B | |
| +17.02% | 246B | |
| +9.26% | 213B | |
| -4.21% | 213B | |
| +2.43% | 167B |
- Stock Market
- Equities
- 300363 Stock
- Financials Porton Pharma Solutions Ltd.
